ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biologics

WuXi invests in North China, Singapore

by Jean-François Tremblay
May 27, 2018 | APPEARED IN VOLUME 96, ISSUE 22

 

The contract manufacturer WuXi Biologics is at it again with major projects planned for Shijiazhuang in North China and Singapore. For its second site in China after Wuxi, near Shanghai, WuXi will spend $240 million on a facility able to support biologics development, clinical production, and commercial manufacturing. Scheduled for completion in 2020, the site will address the “urgent needs of Chinese partners,” WuXi says. Meanwhile, in Singapore, the company will spend $60 million on a smaller-scale plant featuring continuous manufacturing capabilities. Last month, WuXi announced a $390 million investment in Ireland to build what it says will be the world’s largest facility employing single-use bioreactors.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment